InSite Vision to Announce Fourth Quarter and Full Year 2008 Financial Results

InSite Vision Incorporated (AMEX: ISV) announced today that it will release results for the fourth quarter and full year 2008 on Wednesday, March 4.

Louis Drapeau, Chief Executive Officer, will host a conference call beginning at 4:00 PM EST/1:00 PST to discuss these results. Mr. Drapeau will also provide highlights of the company�s strategic plan following several months of review under the leadership of a new management team and Board of Directors.

Investors can submit questions ahead of time prior to the conference call via the company's website at: www.insitevision.com through the "Information Request" tab under the Investor Relations page.

Analysts and investors can listen to the conference call by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 315189.

The live conference call will also be Webcast and available at www.InvestorCalendar.com as well as on the Investor Relations page of the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following completion of the conference call. In addition, the Company's fourth quarter and full year 2008 earnings release will be posted to the Company's Web site and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above.

About InSite Vision

InSite Vision develops novel ocular pharmaceutical products using its DuraSite� bioadhesive polymer core technology to enable topical delivery and sustained release of existing drug molecules for reduced frequency of treatment and improved efficacy. By formulating the well-established antibiotic azithromycin in DuraSite, InSite developed the lowest-dosing ocular antibiotic available to the United States ophthalmic market, AzaSite� (azithromycin ophthalmic solution) 1%, launched by Inspire Pharmaceuticals in the United States for the treatment of bacterial conjunctivitis (pink eye). In addition, InSite has signed licensing and distribution agreements in South Korea; four countries in South America; Turkey; and China; and is seeking other international partners for commercialization and distribution of AzaSite.

InSite is pursuing the expansion of its portfolio of anti-infective ophthalmic products to include ISV-502, which is currently in Phase 3 pivotal trials for the treatment of eye and eyelid infection and inflammation, currently an unmet need. In addition, the company is investigating other product and collaboration opportunities with both the DuraSite-azithromycin platform and/or with DuraSite and other molecules.

Insite Vision (AMEX:ISV)
過去株価チャート
から 5 2024 まで 6 2024